Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery
Head and Neck Cancer, Pain, Postoperative
About this trial
This is an interventional treatment trial for Head and Neck Cancer focused on measuring head and neck cancer, analgesia, pregabalin
Eligibility Criteria
Inclusion Criteria:
- English-speaking patients who are greater than eighteen years of age with a known diagnosis of head and neck cancer and are planned to undergo surgery with bilateral neck dissections will be eligible for this study.
Exclusion Criteria:
- Patients with a history of preoperative narcotic use for conditions unrelated to their head and neck cancer will be excluded.
- Patients younger than eighteen years of age, patients with previous severe adverse reaction to pregabalin (Lyrica), patients with a history of angioedema, and pregnant patients will be excluded from this study.
Sites / Locations
- Augusta University Department of Otolaryngology-Head and Neck Surgery
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Treatment
Control
Treatment arm intervention consists of patients who will be administered a single enteral dose of concealed over-encapsulated Pregabalin 150mg in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
Treatment arm consists of patients who will be administered a single enteral dose of concealed over-encapsulated placebo capsules in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.